Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT06830031 · RECRUITING

Trial details

NCT number: NCT06830031
Sponsor: Shanghai Exuma Biotechnology Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-cell-lymphoma DLBCL, Nos Genetic Subtypes Follicular Lymphoma Grade 3B PMBL HGBL With MYC and BCL2 and/or BCL6 Rearrangements HGBL, Nos

Start date: 2025-03-19
Primary completion: 2026-03-09
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.